ENLIVEN THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 of $0 for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-06.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 · last filed 2022-05-06
- ENLIVEN THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2022-03-31 was $0.00.
- ENLIVEN THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2021-12-31 was $0.00.
- ENLIVEN THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2021-09-30 was $0.00.
- ENLIVEN THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2021-06-30 was $0.00.
- ENLIVEN THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2020 was $0.00.
- ENLIVEN THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2019 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 12 month |
|---|---|---|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-06 | $0.00 derived: sum of 2 quarters · filed 2022-05-06 | $0.00 derived: sum of 3 quarters · filed 2022-05-06 | $0.00 derived: sum of 4 quarters · filed 2022-05-06 |
| 2021-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2022-05-06 | $0.00 derived: sum of 2 quarters · filed 2022-05-06 | $0.00 derived: sum of 3 quarters · filed 2022-05-06 | $0.00 10-Q · filed 2022-05-06 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | $0.00 derived: sum of 4 quarters · filed 2022-03-15 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | $0.00 derived: sum of 4 quarters · filed 2022-03-15 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | $0.00 derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | $0.00 10-K · filed 2022-03-15 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-14 | $0.00 10-Q · filed 2020-08-14 | ||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |